*The following content is generated by AI and is for reference only.
Bivalirudin is a synthetic, direct thrombin inhibitor widely utilized in the management of acute coronary syndromes and during percutaneous coronary interventions (PCI). Its chemical identity is defined by the molecular formula C106H157N31O29S2, with a precise molecular weight of approximately 2,468.7 g/mol. The substance is uniquely identified by its CAS Registry Number, 138039-19-7. Structurally, Bivalirudin consists of a 20-amino acid peptide chain derived from the hirudin family, specifically designed to mimic the active site of natural leech-derived hirudin but with enhanced pharmacokinetic properties and reduced immunogenicity.
The primary clinical application of Bivalirudin lies in its ability to bind reversibly and directly to both the catalytic site and the anion-binding exosite of thrombin. This dual binding mechanism effectively inhibits fibrin formation and platelet aggregation, preventing thrombus growth without relying on antithrombin III as a cofactor, unlike heparin. Consequently, it is frequently administered intravenously to patients undergoing PCI who are at high risk for bleeding or those experiencing heparin-induced thrombocytopenia (HIT). Clinical studies have demonstrated that Bivalirudin offers a comparable efficacy profile to unfractionated heparin while significantly reducing the incidence of major bleeding complications.
Furthermore, due to its short half-life of approximately 25 minutes, Bivalirudin allows for rapid termination of anticoagulant effects upon discontinuation, facilitating immediate hemostasis if surgical intervention becomes necessary. It is typically supplied as a lyophilized powder for reconstitution, ensuring stability prior to administration. While not indicated for long-term oral therapy due to peptide degradation in the gastrointestinal tract, its role in acute cardiac care remains pivotal. Ongoing research continues to explore its potential in other thrombotic disorders, though current guidelines strongly support its use as a safer alternative to heparin in high-risk interventional cardiology settings.